Inhixa (Enoxaparin Sodium)

Enoxaparin Sodium is a low molecular weight heparin used to prevent and treat thromboembolic disorders.

• Deep vein thrombosis (DVT) prevention: reduces the risk of clot formation in surgical or immobilised patients.
• Pulmonary embolism (PE) treatment: facilitates clot resolution and prevents recurrence.
• Anticoagulation during hemodialysis: maintains circuit patency by inhibiting clotting during the procedure.

• Enoxaparin Sodium binds to antithrombin III, accelerating its inhibition of activated factor Xa and, to a lesser extent, thrombin (factor IIa). This selective blockade reduces thrombin generation and fibrin clot formation, providing anticoagulant activity without markedly affecting platelet function.

Enoxaparin Sodium may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Injection site pain or bruising: local irritation at the administration site.
• Minor bleeding: epistaxis, gum bleeding, or easy bruising.
• Nausea or vomiting: gastrointestinal discomfort.
• Headache: mild to moderate intensity.
• Dizziness: transient light‑headedness.
• Elevated liver enzymes: mild, transient changes in hepatic labs.

Serious or Rare Side Effects

• Major hemorrhage: life‑threatening internal bleeding.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop.
• Spinal or epidural hematoma: bleeding in the central nervous system after neuraxial procedures.
• Severe allergic reaction: anaphylaxis or angioedema.
• Disseminated intravascular coagulation (DIC): uncontrolled clotting and bleeding.
• Acute renal failure: rare kidney impairment associated with high doses.

When using Enoxaparin Sodium, clinicians should observe several safety measures.

• Renal impairment: assess kidney function and adjust dose as needed.
• Surgery or invasive procedures: discontinue before to minimise bleeding risk.
• Concomitant anticoagulants or antiplatelet agents: monitor closely for additive bleeding.
• Pregnancy and lactation: use only if the benefit outweighs potential risk.
• Platelet monitoring: check for thrombocytopenia indicative of HIT.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin Sodium can interact with several drug classes, affecting bleeding risk or anticoagulant effect.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, direct thrombin inhibitors): markedly increase bleeding.
• Antiplatelet agents (aspirin, clopidogrel, ticagrelor): additive hemorrhagic risk.
• Fibrinolytic therapy (tPA, streptokinase): potentiate bleeding complications.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): enhance mucosal bleeding.
• Neuraxial anesthesia or spinal puncture: risk of spinal/epidural hematoma.

Moderate Interactions (Monitor Closely)

• Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide): may increase anticoagulant effect.
• Certain antibiotics (e.g., penicillins, cephalosporins): can alter anti‑Xa activity.
• Hormonal therapies (estrogen, oral contraceptives): modestly raise thrombosis risk.